Tags: Frontotemporal Dementia

announcements

New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction

The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.

blog

Loss and Found

Adam Rowe recounts a harrowing experience with his mother, who has frontotemporal dementia. 

announcements

Funding Supports New Approaches to Treat Multiple Types of Dementia

The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.

blog

Types of Dementia (It's Not Just Alzheimer's)

While Alzheimer's accounts for more than two-thirds of dementia cases, the ADDF also funds research to prevent and treat the other causes of dementia.

announcements

New Funding Supports Blood Test for Early Alzheimer’s

The ADDF announces two new grants, including support for a blood test designed to detect Alzheimer’s disease in early stages of development and a gene therapy for frontotemporal dementia.

blog

Dementia & Alzheimer's Disease: What's the Difference?

Our CSO Dr. Fillit explains the differences between Alzheimer's and dementia, two terms often used interchangeably. 

announcements

ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimer's and FTD

A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.

announcements

$4 Million in New Grants Support Several First-in-Class Dementia Treatments

We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.

announcements

Donald Newhouse Honored for His Efforts to End a Rare Form of Dementia

On November 14, Donald Newhouse received The Charles Evans Award from the ADDF at our Seventh Annual Fall Symposium & Luncheon at The Pierre in New York City. Thanks to the generosity of our donors, the Symposium & Luncheon raised nearly $1 million for drug discovery research.

announcements

Lauder and Newhouse Families Announce New Initiative to Find Treatments for Frontotemporal Dementia

The Lauder Foundation, Leonard A. Lauder, President, and Ronald S. Lauder have committed $5 million, which will be combined with $5 million from the Samuel I. Newhouse Foundation to create The Treat FTD Fund. The fund, a joint program of AFTD and the ADDF, will accelerate clinical trials for FTD over the next decade.